Safety of 6000 intravitreal dexamethasone implants

British Journal of Ophthalmology

Volumn 104, Issue 1, 2020, Pages 39-46

  Rajesh, Bindu ^a   Zarranz Ventura, Javier ^b   Fung, Adrian T ^c,d   Busch, Catharina ^e   Sahoo, Niroj Kumar ^f   Rodriguez Valdes, Patricio J ^g   Sarao, Valentina ^h   Mishra, Sanjay Kumar ⁱ   Saatci, A Osman ^j   Udaondo Mirete, Patricia ^k   Querques, Giuseppe ^l   Farah, Michel Eid ^m   Lanzetta, Paolo ^h   Arevalo, J Fernando ⁿ   Kodjikian, Laurent ^o,p   Chhablani, Jay ^f  

^a KHOO TECK PUAT HOSPITAL   (Singapore)

^b HOSPITAL CLÍNIC   (Spain)

^c Westmead University Hospital   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^f L V PRASAD EYE INSTITUTE   (India)

^g SCHOOL OF ENGINEERING AND SCIENCES   (Mexico)

^h UNIVERSITY OF UDINE   (Italy)

ⁱ Department of Laboratory Medicine and Transfusion Medicine   (India)

^j DOKUZ EYLUL UNIVERSITY   (Turkey)

^k HOSPITAL UNIVERSITARIO LA FE   (Spain)

^l SAN RAFFAELE HOSPITAL   (Italy)

^m FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

ⁿ Clinica Oftalmologica Centro Caracas   (Venezuela)

^o CROIX ROUSSE HOSPITAL   (France)

^p UNIVERSITÉ DE LYON   (France)

more..

Author keywords

drugs; treatment medical; vision; vitreous

Indexed keywords

DEXAMETHASONE; GLUCOCORTICOID;

ADULT; ADVERSE OUTCOME; AGED; APHAKIA; ARTICLE; BRANCH RETINAL VEIN OCCLUSION; CATARACT; CATARACT EXTRACTION; CENTRAL MACULAR THICKNESS; CENTRAL RETINA VEIN OCCLUSION; COHORT ANALYSIS; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DISEASE COURSE; DRUG SAFETY; ENDOPHTHALMITIS; FEMALE; FOLLOW UP; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE ABNORMALITY; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIDDLE AGED; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA MACULA CYSTOID EDEMA; RETROSPECTIVE STUDY; UVEITIS; VISUAL ACUITY; VITREOUS HEMORRHAGE; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG IMPLANT; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; MULTICENTER STUDY; RETINA DISEASE; RETINA VEIN OCCLUSION;

AGED; CATARACT; DEXAMETHASONE; DISEASE PROGRESSION; DRUG IMPLANTS; FEMALE; GLAUCOMA; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; RETINAL DISEASES; RETINAL VEIN OCCLUSION; RETROSPECTIVE STUDIES; UVEITIS, POSTERIOR;

EID: 85065248393     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2019-313991     Document Type: Article

References (38)

1. Kim LA, D'Amore PA. A brief history of anti-VEGF for the treatment of ocular angiogenesis. Am J Pathol 2012;181:376-9.
2. Gragoudas ES, Adamis AP, Cunningham ET, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-16.
3. Scholl S, Kirchhof J, Augustin AJ. Pathophysiology of macular edema. Ophthalmologica 2010;224(Suppl 1):8-15.
4. Brown DM, Campochiaro PA, Bhisitkul RB, et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 2011;118:1594-602.
5. Campochiaro PA, Brown DM, Awh CC, et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 2011;118:2041-9.
6. Ip MS, Scott IU, VanVeldhuisen PC, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the standard care vs corticosteroid for retinal vein occlusion (Score) study report 5. Arch Ophthalmol 2009;127:1101-14.
7. Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010;117:1064-77.
8. Sarao V, Veritti D, Boscia F, et al. Intravitreal steroids for the treatment of retinal diseases. Scientific World Journal 2014;2014:1-14.
9. Bulut MN, Çalli Ümit, Göktaş E, et al. Use of an intravitreal dexamethasone implant (Ozurdex) in a case with accidental foveal photocoagulation by Alexandrite laser. Case Rep Ophthalmol 2016;7:130-4.
10. Ozurdex (Dexamethasonr Intravitreal Implant 0.7 mg). Product monograph. ON Canada: Allergan Inc, 2015.
11. Hadayer A, Schaal S. Delivery of steroids into the eye for the treatment of macular edema. Expert Opin Drug Deliv 2016;13:1083-91.
12. Kuppermann BD, Blumenkranz MS, Haller JA, et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 2007;125:309-17.
13. Kuppermann BD, Chou C, Weinberg DV, et al. Intravitreous dexamethasone effects on different patterns of diabetic macular edema. Arch Ophthalmol 2010;128:642-3.
14. Reibaldi M, Russo A, Longo A, et al. Rhegmatogenous retinal detachment with a high risk of proliferative vitreoretinopathy treated with episcleral surgery and an intravitreal dexamethasone 0.7-mg implant. Case Rep Ophthalmol 2013;4:79-83.
15. Russo A, Avitabile T, Uva M, et al. Radiation macular edema after Ru-106 plaque brachytherapy for choroidal melanoma resolved by an intravitreal dexamethasone 0.7-mg implant. Case Rep Ophthalmol 2012;3:71-6.
16. Meyer LM, Schönfeld C-L. Cystoid macular edema after complicated cataract surgery resolved by an intravitreal dexamethasone 0.7-mg implant. Case Rep Ophthalmol 2011;2:319-22.
17. Klamann A, Böttcher K, Ackermann P, et al. Intravitreal dexamethasone implant for the treatment of postoperative macular edema. Ophthalmologica 2016;236:181-5.
18. Lei S, Lam W-C. Efficacy and safety of dexamethasone intravitreal implant for refractory macular edema in children. Can J Ophthalmol 2015;50:236-41.
19. Boyer DS, Yoon YH, Belfort R, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 2014;121:1904-14.
20. Schmitz K, Maier M, Clemens CR, et al. [Reliability and safety of intravitreal Ozurdex injections. The ZERO study]. Ophthalmologe 2014;111:44-52.
21. Blanc J, Kodjikian L, Bron A, et al. Response to safety and long-term efficacy of repeated dexamethasone intravitreal implant for the treatment of cystoid macular edema secondary to retinal vein occlusion with and without a switch to anti-VEGF agents: a 3-year experience. Graefes Arch Clin Exp Ophthalmol 2018;256.
22. Meyer LM, Schönfeld C-L. Secondary glaucoma after intravitreal dexamethasone 0.7 Mg implant in patients with retinal vein occlusion: a one-year follow-up. J Ocul Pharmacol Ther 2013;29:560-5.
23. Malclès A, Dot C, Voirin N, et al. Safety of intravitreal dexamethasone implant (Ozurdex): the SAFODEX study. Incidence and risk factors of ocular hypertension. Retina 2017;37:1352-9.
24. Chylack LT, Wolfe JK, Singer DM, et al. The lens opacities classification system III. the longitudinal study of cataract Study Group. Arch Ophthalmol 1993;111:831-6.
25. Mello Filho P, Andrade G, Maia A, et al. Effectiveness and safety of intravitreal dexamethasone implant (Ozurdex) in patients with diabetic macular edema: A real-world experience. Ophthalmologica 2019;241:9-16.
26. Haller JA, Bandello F, Belfort R, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 2011;118:2453-60.
27. Li X, Wang N, Liang X. Safety and efficacy of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in Chinese patients: randomized, sham-controlled, multicenter study. Graefes Arch Clin Exp Ophthalmol 2018;256:59-69.
28. Eter N, Mohr A, Wachtlin J. Dexamethasone intravitreal implant in retinal vein occlusion:real-life data from a prospective, multicenter clinical trial. Graefes Arch Clin Exp Ophthalmol 2017;255:77-87.
29. Nagpal M, Mehrotra N, Juneja R, et al. Dexamethasone implant (0.7 Mg) in Indian patients with macular edema: real-life scenario. Taiwan J Ophthalmol 2018;8:141-8.
30. Zarranz-Ventura J, Carreño E, Johnston RL, et al. Multicenter study of intravitreal dexamethasone implant in noninfectious uveitis: indications, outcomes, and reinjection frequency. Am J Ophthalmol 2014;158:1136-45.
31. Mayer WJ, Wolf A, Kernt M, et al. Twelve-month experience with Ozurdex for the treatment of macular edema associated with retinal vein occlusion. Eye 2013;27:816-22.
32. Zarranz-Ventura J, Sala-Puigdollers A, Velazquez-Villoria D, et al. Long-term probability of intraocular pressure elevation with the intravitreal dexamethasone implant in the real-world. PLoS One 2019;14:e0209997.
33. Lowder C, Belfort R, Lightman S, et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol 2011;129:545-53.
34. Reid GA, Sahota DS, Sarhan M. Observed complications from dexamethasone intravitreal implant for the treatment of macular edema in retinal vein occlusion over 3 treatment rounds. Retina 2015;35:1647-55.
35. Bakri SJ, Omar AF, Iezzi R, et al. Evaluation of multiple dexamethasone intravitreal implants in patients with macular edema associated with retinal vein occlusion. Retina 2016;36:552-7.
36. Maturi RK, Pollack A, Uy HS, et al. Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year MEAD study. Retina 2016;36:1143-52.
37. Ozkaya A, Tarakcioglu HN, Tanir I. Ranibizumab versus dexamethasone implant in macular edema secondary to branch retinal vein occlusion: two-year outcomes. Optom Vis Sci 2018;95:1149-54.
38. Furino C, Boscia F, Niro A, et al. Combined phacoemulsification and intravitreal dexamethasone implant (Ozurdex®) in diabetic patients with coexisting cataract and diabetic macular edema. J Ophthalmol 2017;2017:1-7.